Journal article
Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer
Expert opinion on biological therapy, Vol.16(10), pp.1209-1223
10/02/2016
DOI: 10.1080/14712598.2016.1214265
PMID: 27426430
Abstract
Introduction: The recent emergence of immune checkpoint blockade therapy and the progression of immunobiology in cancer have spurred an increasing interest in the immunotherapy for advanced non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors (ICIs), designed to directly target immune inhibitory molecules, have demonstrated efficacy in the treatment of patients with advanced NSCLC.
Areas covered: In the present article, the authors summarize the mechanism, efficacy and safety of major ICIs for the treatment of advanced or metastatic NSCLC. Combinations of different ICIs or conventional therapy and/or targeted agents for NSCLC treatment in clinical trials are also updated. In addition, immune-related adverse events and the roles of inhibitory immune checkpoint molecules as potential biomarkers in the immune checkpoint blockade therapy for NSCLC are emphatically elucidated.
Expert opinion: Immunotherapies targeting the immune checkpoint pathways have shown potential to generate durable responses and improve survival for NSCLC patients. Although the toxicity profile of this immunotherapy is manageable, immune-related adverse events and drug resistance may cause therapeutic failure. Therefore, a better understanding of the mechanisms underpinning its function and the potential side effects of ICIs, as well as the identification of predictive biomarkers for patient selection are essential.
Details
- Title: Subtitle
- Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer
- Creators
- Jiali Yang - Center of Laboratory Medicine, General Hospital of Ningxia Medical UniversityJuan Chen - Department of Pulmonary and Critical Care Medicine, General Hospital of Ningxia Medical UniversityJun Wei - Human Stem Cell Institute, General Hospital, Ningxia Medical UniversityXiaoming Liu - Human Stem Cell Institute, General Hospital, Ningxia Medical UniversityWilliam C Cho - Department of Clinical Oncology, Queen Elizabeth Hospital
- Resource Type
- Journal article
- Publication Details
- Expert opinion on biological therapy, Vol.16(10), pp.1209-1223
- Publisher
- Taylor & Francis
- DOI
- 10.1080/14712598.2016.1214265
- PMID
- 27426430
- ISSN
- 1471-2598
- eISSN
- 1744-7682
- Grant note
- 31472191; 81460247 / National Natural Science Foundation of China (10.13039/501100001809)
- Language
- English
- Date published
- 10/02/2016
- Academic Unit
- Anatomy and Cell Biology
- Record Identifier
- 9984025462302771
Metrics
13 Record Views